These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Regulatory T cell abundance and activation status before and after priming with HIVIS-DNA and boosting with MVA-HIV/rgp140/GLA-AF may impact the magnitude of the vaccine-induced immune responses. Chissumba RM; Luciano A; Namalango E; Bauer A; Bhatt N; Wahren B; Nilsson C; Geldmacher C; Scarlatti G; Jani I; Kestens L; Immunobiology; 2018 Dec; 223(12):792-801. PubMed ID: 30121146 [TBL] [Abstract][Full Text] [Related]
24. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Catanzaro AT; Roederer M; Koup RA; Bailer RT; Enama ME; Nason MC; Martin JE; Rucker S; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; Graham BS; Vaccine; 2007 May; 25(20):4085-92. PubMed ID: 17391815 [TBL] [Abstract][Full Text] [Related]
25. Prospects for a globally effective HIV-1 vaccine. Excler JL; Robb ML; Kim JH Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921 [TBL] [Abstract][Full Text] [Related]
26. Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults. Joachim A; Nilsson C; Aboud S; Bakari M; Lyamuya EF; Robb ML; Marovich MA; Earl P; Moss B; Ochsenbauer C; Wahren B; Mhalu F; Sandström E; Biberfeld G; Ferrari G; Polonis VR PLoS One; 2015; 10(4):e0118486. PubMed ID: 25874723 [TBL] [Abstract][Full Text] [Related]
27. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475 [TBL] [Abstract][Full Text] [Related]
28. The RV144 Thai HIV vaccine trial. Plotkin SA Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337 [No Abstract] [Full Text] [Related]
29. HIV-1 phylogenetics and vaccines. Rolland M Curr Opin HIV AIDS; 2019 May; 14(3):227-232. PubMed ID: 30925535 [TBL] [Abstract][Full Text] [Related]
30. RV144: old vs. new. Weiner DB Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335 [No Abstract] [Full Text] [Related]
31. Moving ahead an HIV vaccine: use both arms to beat HIV. Walker BD; Ahmed R; Plotkin S Nat Med; 2011 Oct; 17(10):1194-5. PubMed ID: 21988996 [No Abstract] [Full Text] [Related]
32. Cross-clade neutralizing antibody production against human immunodeficiency virus type 1 clade E and B' strains by recombinant Mycobacterium bovis BCG-based candidate vaccine. Chujoh Y; Matsuo K; Yoshizaki H; Nakasatomi T; Someya K; Okamoto Y; Naganawa S; Haga S; Yoshikura H; Yamazaki A; Yamazaki S; Honda M Vaccine; 2001 Dec; 20(5-6):797-804. PubMed ID: 11738743 [TBL] [Abstract][Full Text] [Related]
33. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques. Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388 [TBL] [Abstract][Full Text] [Related]
34. AIDS vaccines. Glimmerings of hope from the bottom of the well. Cohen J Science; 1999 Jul; 285(5428):656-7. PubMed ID: 10454914 [No Abstract] [Full Text] [Related]
36. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH; J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588 [TBL] [Abstract][Full Text] [Related]
37. Infectious disease. An enterprising time for HIV vaccine research. Cohen J Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300 [No Abstract] [Full Text] [Related]
38. Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. Yu JS; Liao HX; Pritchett J; Bowman C; Vivian C; Parks R; Xia SM; Cooper M; Williams WB; Bonsignori M; Reed SG; Chen M; Vandergrift N; Rice CM; Haynes BF J Virol Methods; 2017 Nov; 249():85-93. PubMed ID: 28837840 [TBL] [Abstract][Full Text] [Related]
39. AIDS research. Novel antibody response may explain HIV vaccine success. Cohen J Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167 [No Abstract] [Full Text] [Related]
40. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies. Ahmed Y; Tian M; Gao Y AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]